[ET Net News Agency, 31 December 2019] Shanghai Junshi Biosciences Co., Ltd. (01877)
said on 30 December 2019, the company entered into a termination agreement with CSPC Group
(01093).
In June 2018, the company entered into a product co-development and strategic
collaboration agreement with CSPC Group in relation to the clinical development,
registration and commercialization of toripalimab in combination with albumin-bound
paclitaxel for the treatment of breast cancer. (RC)